Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Liabilities and Shareholders Equity (2017 - 2025)

Dianthus Therapeutics has reported Liabilities and Shareholders Equity over the past 8 years, most recently at $577.4 million for Q3 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $577.4 million for Q3 2025, up 63.01% from a year ago — trailing twelve months through Sep 2025 was $1.6 billion (up 26.54% YoY), and the annual figure for FY2024 was $374.0 million, up 108.47%.
  • Liabilities and Shareholders Equity for Q3 2025 was $577.4 million at Dianthus Therapeutics, up from $326.1 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for DNTH hit a ceiling of $577.4 million in Q3 2025 and a floor of $78.6 million in Q2 2023.
  • Median Liabilities and Shareholders Equity over the past 4 years was $194.4 million (2022), compared with a mean of $258.8 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: crashed 57.07% in 2023 and later surged 369.19% in 2024.
  • Dianthus Therapeutics' Liabilities and Shareholders Equity stood at $83.1 million in 2022, then soared by 115.86% to $179.4 million in 2023, then surged by 108.47% to $374.0 million in 2024, then surged by 54.39% to $577.4 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $577.4 million (Q3 2025), $326.1 million (Q2 2025), and $348.6 million (Q1 2025) per Business Quant data.